The struggling pathology company told investors it had engaged advisers to sell Lumus Imaging as it focuses on reinvigorating its core pathology business.
Tucked away in private equity, it is easy to forget about Australia’s biggest imaging company I-MED. But it is worth watching this year; it has a few ideas on the boil.
The company replaced its chief executive, Maxine Jacquet, earlier this month after just 12 months. It runs some 2000 pathology centres and 100 laboratories.
Healius Limited (ASX:HLS – Get Free Report) insider Kathryn (Kate) McKenzie bought 53,000 shares of Healius stock in a transaction on Monday, December 4th. The stock was acquired at an average cost of A$1.52 ($1.01) per share, with a total value of A$80,560.00 ($53,350.99). Healius Stock Performance The company has a current ratio of 0.55, […]
There’s restructuring ahead at the No. 2 pathology provider Healius, which despite its activist ructions, has yielded a 30 per cent return since its 2023 low.